RT-23 THE ROLE OF GAMMA KNIFE RADIOSURGERY IN THE TREATMENT FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS

To evaluate the role of gamma knife (GK) as a treatment modality for primary central nervous system lymphomas (PCNSL), we reviewed PCNSL patients who were treated with GK between November 2004 and May 2014, retrospectively. There were 29 cases (13 males and 16 females, ranged from 33 years old to 91...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2014-11, Vol.16 (suppl 5), p.v192-v192
Hauptverfasser: Mori, K., Chiba, Y., Toyota, S., Kumagai, T., Yamamoto, S., Sugano, H., Taki, T.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page v192
container_issue suppl 5
container_start_page v192
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 16
creator Mori, K.
Chiba, Y.
Toyota, S.
Kumagai, T.
Yamamoto, S.
Sugano, H.
Taki, T.
description To evaluate the role of gamma knife (GK) as a treatment modality for primary central nervous system lymphomas (PCNSL), we reviewed PCNSL patients who were treated with GK between November 2004 and May 2014, retrospectively. There were 29 cases (13 males and 16 females, ranged from 33 years old to 91 years old) with 210 treated lesions. Marginal dose was from 12Gy to 18 Gy. One hundred and nineteen lesions of 23 cases could be accessed and all of them showed partial response or complete response. In seven cases, GK was performed at initial treatment, in 18 cases at recurrence, and in four cases at both. Median age of initial treatment group were significantly higher than that of recurred group (77.8 y.o. and 63.6 y.o., p = 0.00268). Two cases of initial treatment group and 16 cases of recurrent group were treated with whole brain radiation therapy (WBRT). GK after first relapse, progression free survival more than six months were obtained for six cases (33.3%), and four of them were free from additional therapy more than one year. Otherwise, thirteen cases (59.1%) received GK repeatedly (2-6 times, median = 3), and interval between each therapy was from 22 to 513 days (median = 93days). We confirmed that GK has high potential for local control. And it was supposed that GK was used as an alternative to WBRT at initial treatment for elderly, or selected to recurrent cases after WBRT. These results showed the role of GK in the treatment for PCNSL is palliative care, now in Japan. But it is clear that there exist patients who can live longer without WBRT by GK. We conclude that GK will become to play a more positive role by modifying its timing and modalities used together.
doi_str_mv 10.1093/neuonc/nou270.20
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808632068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1808632068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1160-1ec55aeb8ae381099dd00c842edd6e5927f3fd0f3b45e904367d4f4bdb5a84763</originalsourceid><addsrcrecordid>eNotkDtPwzAURi0EEqWwM3pkSetH7DhjVNw2Io_KSZE6WXk4oqhNSkwG_j2hYbpX33d0pXsAeMZogZFPl60ZurZatt1APLQg6AbMMCPUYYLz2-tOHMGwdw8erP1EiGDG8Qx8qNwhFOZbCVUaSZiu4SaI4wC-JeF6zILXMM32aiPVAYbJlcuVDPJYJjlcpwruVBgHY7kaAxVEMJHqPd1nMDtkuYxhdIh32zQOskdw1xQna57-5xzs1zJfbZ0o3YSrIHIqjDlysKkYK0wpCkPF-Jhf1whVwiWmrrlhPvEa2tSooaXLjI9cyr3abdyyLlkhXI_TOXiZ7l767msw9lufj7Yyp1PRmm6wGgskOCWIixFFE1r1nbW9afSlP56L_kdjpP-k6kmqnqRqgugvAjFkOw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1808632068</pqid></control><display><type>article</type><title>RT-23 THE ROLE OF GAMMA KNIFE RADIOSURGERY IN THE TREATMENT FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>PubMed Central</source><creator>Mori, K. ; Chiba, Y. ; Toyota, S. ; Kumagai, T. ; Yamamoto, S. ; Sugano, H. ; Taki, T.</creator><creatorcontrib>Mori, K. ; Chiba, Y. ; Toyota, S. ; Kumagai, T. ; Yamamoto, S. ; Sugano, H. ; Taki, T.</creatorcontrib><description>To evaluate the role of gamma knife (GK) as a treatment modality for primary central nervous system lymphomas (PCNSL), we reviewed PCNSL patients who were treated with GK between November 2004 and May 2014, retrospectively. There were 29 cases (13 males and 16 females, ranged from 33 years old to 91 years old) with 210 treated lesions. Marginal dose was from 12Gy to 18 Gy. One hundred and nineteen lesions of 23 cases could be accessed and all of them showed partial response or complete response. In seven cases, GK was performed at initial treatment, in 18 cases at recurrence, and in four cases at both. Median age of initial treatment group were significantly higher than that of recurred group (77.8 y.o. and 63.6 y.o., p = 0.00268). Two cases of initial treatment group and 16 cases of recurrent group were treated with whole brain radiation therapy (WBRT). GK after first relapse, progression free survival more than six months were obtained for six cases (33.3%), and four of them were free from additional therapy more than one year. Otherwise, thirteen cases (59.1%) received GK repeatedly (2-6 times, median = 3), and interval between each therapy was from 22 to 513 days (median = 93days). We confirmed that GK has high potential for local control. And it was supposed that GK was used as an alternative to WBRT at initial treatment for elderly, or selected to recurrent cases after WBRT. These results showed the role of GK in the treatment for PCNSL is palliative care, now in Japan. But it is clear that there exist patients who can live longer without WBRT by GK. We conclude that GK will become to play a more positive role by modifying its timing and modalities used together.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/nou270.20</identifier><language>eng</language><ispartof>Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v192-v192</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>Mori, K.</creatorcontrib><creatorcontrib>Chiba, Y.</creatorcontrib><creatorcontrib>Toyota, S.</creatorcontrib><creatorcontrib>Kumagai, T.</creatorcontrib><creatorcontrib>Yamamoto, S.</creatorcontrib><creatorcontrib>Sugano, H.</creatorcontrib><creatorcontrib>Taki, T.</creatorcontrib><title>RT-23 THE ROLE OF GAMMA KNIFE RADIOSURGERY IN THE TREATMENT FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>To evaluate the role of gamma knife (GK) as a treatment modality for primary central nervous system lymphomas (PCNSL), we reviewed PCNSL patients who were treated with GK between November 2004 and May 2014, retrospectively. There were 29 cases (13 males and 16 females, ranged from 33 years old to 91 years old) with 210 treated lesions. Marginal dose was from 12Gy to 18 Gy. One hundred and nineteen lesions of 23 cases could be accessed and all of them showed partial response or complete response. In seven cases, GK was performed at initial treatment, in 18 cases at recurrence, and in four cases at both. Median age of initial treatment group were significantly higher than that of recurred group (77.8 y.o. and 63.6 y.o., p = 0.00268). Two cases of initial treatment group and 16 cases of recurrent group were treated with whole brain radiation therapy (WBRT). GK after first relapse, progression free survival more than six months were obtained for six cases (33.3%), and four of them were free from additional therapy more than one year. Otherwise, thirteen cases (59.1%) received GK repeatedly (2-6 times, median = 3), and interval between each therapy was from 22 to 513 days (median = 93days). We confirmed that GK has high potential for local control. And it was supposed that GK was used as an alternative to WBRT at initial treatment for elderly, or selected to recurrent cases after WBRT. These results showed the role of GK in the treatment for PCNSL is palliative care, now in Japan. But it is clear that there exist patients who can live longer without WBRT by GK. We conclude that GK will become to play a more positive role by modifying its timing and modalities used together.</description><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNotkDtPwzAURi0EEqWwM3pkSetH7DhjVNw2Io_KSZE6WXk4oqhNSkwG_j2hYbpX33d0pXsAeMZogZFPl60ZurZatt1APLQg6AbMMCPUYYLz2-tOHMGwdw8erP1EiGDG8Qx8qNwhFOZbCVUaSZiu4SaI4wC-JeF6zILXMM32aiPVAYbJlcuVDPJYJjlcpwruVBgHY7kaAxVEMJHqPd1nMDtkuYxhdIh32zQOskdw1xQna57-5xzs1zJfbZ0o3YSrIHIqjDlysKkYK0wpCkPF-Jhf1whVwiWmrrlhPvEa2tSooaXLjI9cyr3abdyyLlkhXI_TOXiZ7l767msw9lufj7Yyp1PRmm6wGgskOCWIixFFE1r1nbW9afSlP56L_kdjpP-k6kmqnqRqgugvAjFkOw</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Mori, K.</creator><creator>Chiba, Y.</creator><creator>Toyota, S.</creator><creator>Kumagai, T.</creator><creator>Yamamoto, S.</creator><creator>Sugano, H.</creator><creator>Taki, T.</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20141101</creationdate><title>RT-23 THE ROLE OF GAMMA KNIFE RADIOSURGERY IN THE TREATMENT FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS</title><author>Mori, K. ; Chiba, Y. ; Toyota, S. ; Kumagai, T. ; Yamamoto, S. ; Sugano, H. ; Taki, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1160-1ec55aeb8ae381099dd00c842edd6e5927f3fd0f3b45e904367d4f4bdb5a84763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mori, K.</creatorcontrib><creatorcontrib>Chiba, Y.</creatorcontrib><creatorcontrib>Toyota, S.</creatorcontrib><creatorcontrib>Kumagai, T.</creatorcontrib><creatorcontrib>Yamamoto, S.</creatorcontrib><creatorcontrib>Sugano, H.</creatorcontrib><creatorcontrib>Taki, T.</creatorcontrib><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mori, K.</au><au>Chiba, Y.</au><au>Toyota, S.</au><au>Kumagai, T.</au><au>Yamamoto, S.</au><au>Sugano, H.</au><au>Taki, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RT-23 THE ROLE OF GAMMA KNIFE RADIOSURGERY IN THE TREATMENT FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2014-11-01</date><risdate>2014</risdate><volume>16</volume><issue>suppl 5</issue><spage>v192</spage><epage>v192</epage><pages>v192-v192</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>To evaluate the role of gamma knife (GK) as a treatment modality for primary central nervous system lymphomas (PCNSL), we reviewed PCNSL patients who were treated with GK between November 2004 and May 2014, retrospectively. There were 29 cases (13 males and 16 females, ranged from 33 years old to 91 years old) with 210 treated lesions. Marginal dose was from 12Gy to 18 Gy. One hundred and nineteen lesions of 23 cases could be accessed and all of them showed partial response or complete response. In seven cases, GK was performed at initial treatment, in 18 cases at recurrence, and in four cases at both. Median age of initial treatment group were significantly higher than that of recurred group (77.8 y.o. and 63.6 y.o., p = 0.00268). Two cases of initial treatment group and 16 cases of recurrent group were treated with whole brain radiation therapy (WBRT). GK after first relapse, progression free survival more than six months were obtained for six cases (33.3%), and four of them were free from additional therapy more than one year. Otherwise, thirteen cases (59.1%) received GK repeatedly (2-6 times, median = 3), and interval between each therapy was from 22 to 513 days (median = 93days). We confirmed that GK has high potential for local control. And it was supposed that GK was used as an alternative to WBRT at initial treatment for elderly, or selected to recurrent cases after WBRT. These results showed the role of GK in the treatment for PCNSL is palliative care, now in Japan. But it is clear that there exist patients who can live longer without WBRT by GK. We conclude that GK will become to play a more positive role by modifying its timing and modalities used together.</abstract><doi>10.1093/neuonc/nou270.20</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v192-v192
issn 1522-8517
1523-5866
language eng
recordid cdi_proquest_miscellaneous_1808632068
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); PubMed Central
title RT-23 THE ROLE OF GAMMA KNIFE RADIOSURGERY IN THE TREATMENT FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T12%3A32%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RT-23%20THE%20ROLE%20OF%20GAMMA%20KNIFE%20RADIOSURGERY%20IN%20THE%20TREATMENT%20FOR%20PRIMARY%20CENTRAL%20NERVOUS%20SYSTEM%20LYMPHOMAS&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Mori,%20K.&rft.date=2014-11-01&rft.volume=16&rft.issue=suppl%205&rft.spage=v192&rft.epage=v192&rft.pages=v192-v192&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/nou270.20&rft_dat=%3Cproquest_cross%3E1808632068%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1808632068&rft_id=info:pmid/&rfr_iscdi=true